Arundati Ramesh, MD
Geriatric Medicine · Murfreesboro, TNNPI 1154392918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.1% of the total. Reporting peaked in 2022 at $444 and has fallen 55.5% since, to $198 in 2025.
Across 101 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$496
- Novo Nordisk$183
- Astellas Pharma US Inc$166
- Lilly USA, LLC$125
- GSK$117
- Valeritas, Inc.$106
- plus $399 from 13 others
What the payments were for
- Food & beverage$1,593100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $496 |
| Novo Nordisk | 14 | $183 |
| Astellas Pharma US Inc | 10 | $166 |
| Lilly USA, LLC | 8 | $125 |
| GSK | 8 | $117 |
| Valeritas, Inc. | 1 | $106 |
| Amgen | 6 | $99 |
| Pfizer | 3 | $46 |
| Johnson & Johnson | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $32 |
| Medtronic | 1 | $27 |
| Merck | 2 | $26 |
| Dexcom, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Bayer | 1 | $13 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V-GO$106
How this compares
$1,593 in reported general payments places this provider in the 80th percentile of 46 geriatric medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $140,597 |
| OzempicSemaglutide | 85 | $97,587 |
| MounjaroTirzepatide | 64 | $81,814 |
| EliquisApixaban | 59 | $61,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $34,901 |
| JanuviaSitagliptin Phosphate | 21 | $31,909 |
| RybelsusSemaglutide | 11 | $29,984 |
| XareltoRivaroxaban | 18 | $15,494 |
| MyrbetriqMirabegron | 14 | $13,790 |
| Repatha SureclickEvolocumab | 17 | $11,372 |
| Atorvastatin Calcium | 797 | $9,107 |
| LinzessLinaclotide | 13 | $8,635 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,320 |
| Risedronate Sodium | 53 | $7,055 |
| BelsomraSuvorexant | 16 | $6,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $13 | $140,597126 claims |
| Novo NordiskOzempic, Rybelsus | $183 | $127,57196 claims |
| Lilly USA, LLCMounjaro | $125 | $81,81464 claims |
| PfizerEliquis | $46 | $61,61059 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $117 | $49,34391 claims |
| MerckJanuvia, Belsomra | $26 | $38,66137 claims |
| Johnson & JohnsonXarelto | $43 | $15,49418 claims |
| AbbVieLinzess, Synthroid | $496 | $14,840106 claims |
| Astellas Pharma US IncMyrbetriq | $166 | $13,79014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 geriatric medicine providers in Tennessee.
Other geriatric medicine in Murfreesboro
- Geetha GovindaswamyMurfreesboro$15
- Ronald HamdyJohnson City$69K
- Kenneth DozierMadison$9K
- Lotika PanditChattanooga$8K
- Terry MelvinChattanooga$7K
- Monica CraneKnoxville$7K
- Raul CouretHendersonville$6K
- Kevin JamesMaryville$4K
- Monica WarhaftigMemphis$3K
- Kendra SheppardMemphis$985
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.